Risk Factors for Brain Metastases in Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

被引:10
作者
Zeng, Haiyan [1 ]
Zheng, Danyang [2 ,3 ]
Witlox, Willem J. A. [4 ]
Levy, Antonin [5 ,6 ]
Traverso, Alberto [1 ]
Kong, Feng-Ming [2 ,3 ]
Houben, Ruud [1 ]
De Ruysscher, Dirk K. M. [1 ]
Hendriks, Lizza E. L. [7 ]
机构
[1] Maastricht Univ Med Ctr, GROW Sch Oncol, Dept Radiat Oncol Maastro, Maastricht, Netherlands
[2] Univ Hong Kong, Li Ka Shing Fac Med, Dept Clin Oncol, Hong Kong, Peoples R China
[3] Univ Hong Kong, Shenzhen Hosp, Dept Clin Oncol, Shenzhen, Peoples R China
[4] Maastricht Univ Med Ctr, GROW Sch Oncol & Dev Biol, Dept Clin Epidemiol & Med Technol Assessment, Maastricht, Netherlands
[5] Gustave Roussy, Dept Radiat Oncol, Villejuif, France
[6] Univ Paris Saclay, Fac Med, Le Kremlin Bicetre, France
[7] Maastricht Univ Med Ctr, GROW Sch Oncol & Dev Biol, Dept Pulm Dis, Maastricht, Netherlands
关键词
small cell lung cancer; brain metastasis; risk factors; systematic review; meta-analysis; PROPHYLACTIC CRANIAL IRRADIATION; RANDOMIZED PHASE-II; LIMITED-STAGE; THORACIC RADIOTHERAPY; COMPLETE REMISSION; RADIATION-THERAPY; CLINICAL-TRIAL; CHEMOTHERAPY; SURVIVAL; CHEMORADIOTHERAPY;
D O I
10.3389/fonc.2022.889161
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The use of prophylactic cranial irradiation (PCI) for small cell lung cancer (SCLC) patients is controversial. Risk factors for brain metastasis (BM) development are largely lacking, hampering personalized treatment strategies. This study aimed to identify the possible risk factors for BM in SCLC.We systematically searched the Pubmed database (1 January 1995 to 18 January 2021) according to the PRISMA guidelines. Eligibility criteria: studies reporting detailed BM data with an adequate sample size (randomized clinical trials [RCTs]: N >= 50; non-RCTs: N >= 100) in patients with SCLC. We summarized the reported risk factors and performed meta-analysis to estimate the pooled hazard ratios (HR) if enough qualified data (i.e., two or more studies; the same study type; the same analysis method; and HRs retrievable) were available. In total, 61/536 records were eligible (18 RCTs and 39 non-RCTs comprising 13,188 patients), in which 57 factors were reported. Ten factors qualified BM data for meta-analysis: Limited stage disease (LD) (HR = 0.34, 95% CI: 0.17-0.67; P = 0.002) and older age (>= 65) (HR = 0.70, 95% CI: 0.54-0.92; P = 0.01) were associated with less BM; A higher T stage (>= T3) (HR = 1.72, 95% CI: 1.16-2.56; P = 0.007) was a significant risk factor for BM. Male sex (HR = 1.24, 95% CI: 0.99-1.54; P = 0.06) tended to be a risk factor, and better PS (0-1) (HR = 0.66, 95% CI: 0.42-1.02; P = 0.06) tended to have less BM. Smoking, thoracic radiotherapy dose were not significant (P > 0.05). PCI significantly decreased BM (P < 0.001), but did not improve OS in ED-SCLC (P = 0.81). A higher PCI dose did not improve OS (P = 0.11). The impact on BM was conflicting between Cox regression data (HR = 0.59, 95% CI: 0.26-1.31; P = 0.20) and competing risk regression data (HR = 0.74, 95% CI: 0.55-0.99; P = 0.04). Compared to M0-M1a, M1b was a risk factor for OS (P = 0.01) in ED-SCLC, but not for BM (P = 0.19). As regular brain imaging is rarely performed, high-quality data is lacking. Other factors such as N-stage and blood biomarkers had no qualified data to perform meta-analysis. In conclusion, younger age, higher T stage, and ED are risk factors for BM, suggesting that PCI should be especially discussed in such cases. Individual patient data (IPD) meta-analysis and well-designed RCTs are needed to better identify more risk factors and further confirm our findings.
引用
收藏
页数:41
相关论文
共 105 条
[31]   Selecting Patients with Extensive-Stage Small Cell Lung Cancer for Prophylactic Cranial Irradiation by Predicting Brain Metastases [J].
Greenspoon, Jeffrey N. ;
Evans, William K. ;
Cai, Wenjie ;
Wright, James R. .
JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (04) :808-812
[32]   Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: A European organization for research and treatment of cancer lung cancer cooperative group study [J].
Gregor, A ;
Drings, P ;
Burghouts, J ;
Postmus, PE ;
Morgan, D ;
Sahmoud, T ;
Kirkpatrick, A ;
Dalesio, O ;
Giaccone, G .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (08) :2840-2849
[33]   Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: Results of a multicentre randomised trial [J].
Gregor, A ;
Cull, A ;
Stephens, RJ ;
Kirkpatrick, JA ;
Yarnold, JR ;
Girling, DJ ;
Macbeth, FR ;
Stout, R ;
Machin, D .
EUROPEAN JOURNAL OF CANCER, 1997, 33 (11) :1752-1758
[34]   Long-term survival with metastatic cancer to the brain [J].
Hall, WA ;
Djalilian, HR ;
Nussbaum, ES ;
Cho, KH .
MEDICAL ONCOLOGY, 2000, 17 (04) :279-286
[35]   Measuring inconsistency in meta-analyses [J].
Higgins, JPT ;
Thompson, SG ;
Deeks, JJ ;
Altman, DG .
BMJ-BRITISH MEDICAL JOURNAL, 2003, 327 (7414) :557-560
[36]  
Higgins JPT, 2020, J Multidiscip Eval, DOI [DOI 10.1002/9781119536604, 10.1002/9781119536604]
[37]  
Higginst J., 2021, COCHRANE HDB SYSTEMA
[38]   Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: A randomized study [J].
Jeremic, B ;
Shibamoto, Y ;
Acimovic, L ;
Milisavljevic, S .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (03) :893-900
[39]   Role of prophylactic cranial irradiation for elderly patients with limited-disease small-cell lung cancer: inverse probability of treatment weighting using propensity score [J].
Kim, Tae Gyu ;
Pyo, Hongryull ;
Ahn, Yong Chan ;
Noh, Jae Myoung ;
Oh, Dongryul .
JOURNAL OF RADIATION RESEARCH, 2019, 60 (05) :630-638
[40]   Controlled clinical trial of prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission [J].
Laplanche, A ;
Monnet, I ;
Santos-Miranda, JA ;
Bardet, E ;
Le Pechoux, C ;
Tarayre, M ;
Arriagada, R .
LUNG CANCER, 1998, 21 (03) :193-201